Related Experiment Videos
Prostate cancer prevention by silibinin.
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Cancer Center, 4200 East Ninth Avenue, Denver, CO 80262, USA.
Current Cancer Drug Targets
|February 18, 2004
Summary
Silibinin/silymarin, a natural compound, shows potent anti-cancer effects against prostate cancer (PCA) by inhibiting tumor growth and angiogenesis. This natural agent is now in clinical trials for PCA patients.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- Prostate cancer (PCA) growth is driven by epigenetic alterations, leading to uncontrolled cell proliferation and angiogenesis.
- Targeting epigenetic mechanisms offers a promising strategy for PCA prevention and treatment.
- Silibinin/silymarin exhibits significant anticancer properties against PCA.
Purpose of the Study:
- To investigate the anticancer effects and mechanisms of silibinin/silymarin in prostate cancer.
- To evaluate silibinin/silymarin's potential in PCA prevention, growth control, and treatment.
- To explore silibinin/silymarin's role in inhibiting PCA progression and angiogenesis.
Main Methods:
- In vitro studies using PCA cell lines.
- In vivo studies using nude mice xenograft models.
- Analysis of cell cycle, signaling pathways (EGFR, IGF-IR, NF-κB), and endothelial cell function.
Main Results:
- Silibinin/silymarin demonstrated pleiotropic anticancer effects, inhibiting PCA cell growth in vitro and in vivo.
- Mechanisms include cell cycle alteration, inhibition of mitogenic/survival signaling, and suppression of angiogenesis.
- Silibinin synergized doxorubicin's efficacy and inhibited tumor xenograft growth in mice.
Conclusions:
- Silibinin/silymarin possesses strong preventive and therapeutic potential for prostate cancer.
- Its non-toxic, mechanism-based action makes it a viable candidate for combination chemotherapy and clinical trials.
- Silibinin is currently in Phase I clinical trials for prostate cancer patients.